Radiopharmaceuticals heat anti-tumor immunity

Qi Sun; Jiyuan Li; Zexuan Ding; Zhibo Liu

doi:10.7150/thno.79806

Radiopharmaceuticals heat anti-tumor immunity

Theranostics. 2023 Jan 1;13(2):767-786. doi: 10.7150/thno.79806. eCollection 2023.

Authors

Qi Sun¹, Jiyuan Li², Zexuan Ding³, Zhibo Liu^{1

2

3}

Affiliations

¹ Peking University-Tsinghua University Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
² Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
³ Changping Laboratory, Beijing 102206, China.

Abstract

Radiopharmaceutical therapy (RPT) has proven to be an effective cancer treatment with minimal toxicity. With several RPT agents approved by FDA, the remarkable potential of this therapy is now being recognized, and the anti-tumor immunity induced by RPT is beginning to be noticed. This review evaluates the potential of RPT for immune activation, including promoting the release of danger associated-molecular pattern molecules that recruit inflammatory cells into the tumor microenvironment, and activating antigen-presenting cells and cytotoxic T cells. We also discuss the progress of combining RPT with immunotherapy to increase efficacy.

Keywords: anti-tumor immunity; immunogenic cell death (ICD); radiopharmaceutical therapy (RPT).

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Hot Temperature
Humans
Immunotherapy
Neoplasms* / therapy
Radiopharmaceuticals* / therapeutic use
T-Lymphocytes, Cytotoxic
Tumor Microenvironment

Substances

Radiopharmaceuticals